UBS Group
RADX

UBS Group’s Radiopharm Theranostics RADX Stock Holding History

UBS Group’s Portfolio RADX Stock Details RADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9K Sell
3,000
-11,277
-79% -$55.1K ﹤0.01% 8236
2025
Q4 		$74.5K Sell
14,277
-3,914
-22% -$20.8K ﹤0.01% 7044
2025
Q3 		$100K Buy
18,191
+451
+3% +$2.36K ﹤0.01% 7127
2025
Q2 		$82.3K Buy
+17,740
New +$79.6K ﹤0.01% 7394
2025
Q1 		– Sell
-1,317
Closed -$5.91K – 10921
2024
Q4 		$5.91K Buy
+1,317
New +$8.66K ﹤0.01% 8611

Other funds holding RADX

SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group's RADX Position: Q1 2026 in Review

UBS Group reduced its Radiopharm Theranostics (RADX) stake by 79% in Q1 2026, selling an estimated $55.1K and leaving 3,000 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8236.

UBS Group first reported a position in RADX in Q4 2024 and has held it in 5 quarters since. The position peaked at $100K in Q3 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

  • UBS Group held 3,000 shares of Radiopharm Theranostics worth $12.9K as of Q1 2026.
  • UBS Group sold 11,277 Radiopharm Theranostics shares in Q1 2026, an estimated $55.1K.
  • Radiopharm Theranostics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8236 holding.
  • UBS Group first reported a position in Radiopharm Theranostics in Q4 2024 and has held it in 5 quarters since.
  • UBS Group's Radiopharm Theranostics position peaked at $100K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.